Global Non-Invasive Prenatal Testing Market Size, Share, Growth, Trends, and Forecast (2024 - 2031)
Global Non-Invasive Prenatal Testing Market Scope: Historical Data (2021 – 2022), Base Year (2023), Forecast Period (2024 – 2031)
Market Segmentation: By Method (Ultrasound Detection, Biochemical Screening Tests, and Cell-Free DNA in Maternal Plasma Tests), Technology (NGS, Array Technology, PCR, and Others), Product (Consumables & Reagents, and Instruments), End Use (Hospitals & Clinics, and Diagnostic Laboratories), and Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)
Market Overview
The Global Non-Invasive Prenatal Testing Market was valued at USD 5,396.7 million in 2023 and is expected to reach USD 11,995.7 million by 2031 while growing at a CAGR of 10.5% during the forecast period (2024-2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Market Dynamics
This section of the report will analyze various driving and restraining factors that are expected to have a significant impact on the global non-invasive prenatal testing market growth. Non-Invasive Prenatal Testing (NIPT) evaluates the risk of chromosomal abnormalities in a fetus during pregnancy by analyzing cell-free fetal DNA (cffDNA) in the maternal bloodstream, unlike invasive methods like amniocentesis or chorionic villus sampling (CVS) which pose a small risk of miscarriage.
Continuous advancements in molecular biology, sequencing technologies, and bioinformatics algorithms, along with the rising prevalence of chromosomal abnormalities, drive the growth of non-invasive prenatal testing (NIPT). However, hinderances such as the cost of testing, as well as regulatory and ethical considerations, impede the market's expansion.
Furthermore, the global non-invasive prenatal testing industry will be analyzed through various tools including PESTLE analysis, and Porter’s analysis.
Segmentation – By Method Analysis
The Global Non-Invasive Prenatal Testing Market is segmented among Ultrasound Detection, Biochemical Screening Tests, and Cell-Free DNA in Maternal Plasma Tests, based on Method. In 2023, Cell-Free DNA in Maternal Plasma Tests accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Segmentation – By Technology Analysis
The Global Non-Invasive Prenatal Testing Market is segmented among NGS, Array Technology, PCR, and Others, based on Technology. In 2023, NGS accounted for the majority of the market share*.
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Global Non-Invasive Prenatal Testing Market: Regional Analysis
Based on region, the market is divided into six regions including North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. In 2023, North America dominated the market with the highest market share, while Asia Pacific is expected to grow with the highest CAGR during the forecast period (2024 – 2031).
*Note: Graph is shown for illustrative purposes only; complete datasets will be provided in the full report
Competitive Landscape
Some of the key players operating in the market are Genesis Genetics (CooperSurgical, Inc.), Natera, Inc., Eurofins LifeCodexx GmbH, Illumina, Inc. (Verinata Health, Inc.), Centogene N.V., MedGenome Labs Ltd., Myriad Women’s Health, Inc. (Counsyl, Inc.), F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics), Qiagen, Laboratory Corp. of America Holdings, Progenity, Inc., and Quest Diagnostics, Inc.
Table of Contents:
1. Research Methodology and Market Scope
Research Methodology
Market Scope
2. Executive Summary
3. Global Non-Invasive Prenatal Testing Market Dynamics
Drivers
Restraints
Opportunity
4. Global Non-Invasive Prenatal Testing Industry Analysis
PEST Analysis
Porter's Five Force Analysis
Recent Deals Analysis
5. Global Non-Invasive Prenatal Testing Market Segmentation, By Method
Global Non-Invasive Prenatal Testing Market Share Analysis, By Method
Global Non-Invasive Prenatal Testing Market Growth Analysis, By Method
Global Non-Invasive Prenatal Testing Market Trends, By Method
o Ultrasound Detection
o Biochemical Screening Tests
o Cell-Free DNA in Maternal Plasma Tests
6. Global Non-Invasive Prenatal Testing Market Segmentation, By Technology
Global Non-Invasive Prenatal Testing Market Share Analysis, By Technology
Global Non-Invasive Prenatal Testing Market Growth Analysis, By Technology
Global Non-Invasive Prenatal Testing Market Trends, By Technology
o NGS
o Array Technology
o PCR
o Others
7. Global Non-Invasive Prenatal Testing Market Segmentation, By Product
Global Non-Invasive Prenatal Testing Market Share Analysis, By Product
Global Non-Invasive Prenatal Testing Market Growth Analysis, By Product
Global Non-Invasive Prenatal Testing Market Trends, By Product
o Consumables & Reagents
o Instruments
8. Global Non-Invasive Prenatal Testing Market Segmentation, By End User
Global Non-Invasive Prenatal Testing Market Share Analysis, By End User
Global Non-Invasive Prenatal Testing Market Growth Analysis, By End User
Global Non-Invasive Prenatal Testing Market Trends, By End User
o Hospitals & Clinics
o Diagnostic Laboratories
9. Global Non-Invasive Prenatal Testing Market Segmentation, By Region
Global Non-Invasive Prenatal Testing Market Share Analysis, By Region
Global Non-Invasive Prenatal Testing Market Growth Analysis, By Region
Global Non-Invasive Prenatal Testing Market Trends, By Region
o North America
o Europe
o Asia Pacific
o Latin America
o Middle East
o Africa
10. Competitive Landscape
Genesis Genetics (CooperSurgical, Inc.)*
o Company Overview
o Financial Performance
o Key Development/Strategies
o SWOT Analysis
Natera, Inc.
Eurofins LifeCodexx GmbH
Illumina, Inc. (Verinata Health, Inc.)
Centogene N.V.
MedGenome Labs Ltd.
Myriad Women’s Health, Inc. (Counsyl, Inc.)
F. Hoffmann-La Roche Ltd. (Ariosa Diagnostics)
Qiagen
Laboratory Corp. of America Holdings
Progenity, Inc.
Quest Diagnostics, Inc.
*Similar analysis will be provided for each company listed above.
